CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
dexamethasone +2 moredrug
Likely dose
dexamethasone 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00679367
NCT00679367Phase 2Completed
CompareCT.gov

A Phase II Trial of MRD (Melphalan, Lenalidomide and Dexamethasone) for Patients With AL Amyloidosis

Boston Medical Center·interventional·Posted May 16, 2008·Updated Feb 20, 2017

In Brief

A Phase 2 clinical trial evaluating dexamethasone, lenalidomide, and 1 other intervention for Multiple Myeloma. Completed, enrolled 16 participants across 1 site.

Detailed Summary

RATIONALE: Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of abnormal plasma cells, either by killing the cells or by stopping them from dividing. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop the abnormal plasma cells from growing. Giving melphalan together with lenalidomide and dexamethasone may be an effective treatment for primary systemic amyloidosis. PURPOSE: This phase II trial is studying the side effects and how well giving melphalan together with lenalidomide and dexamethasone works in treating patients with primary systemic amyloidosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 16, 2008
Enrollment StartMay 1, 2008
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7 yearsPosted 18.1 years ago

Interventions

dexamethasonedrug

40 mg once weekly

lenalidomidedrug

10 mg/day D1-21

melphalandrug

5 mg/m2 D1-4